Skip to content

A Randomized, Double-Blind, Placebo-Controlled, Self-Controlled Study on the Analgesic-Enhancing Effect of Brimonidine Tartrate Eye Drops as an Adjunct to Compound Lidocaine Cream

A Randomized, Double-Blind, Placebo-Controlled, Self-Controlled Study on the Analgesic-Enhancing Effect of Brimonidine Tartrate Eye Drops as an Adjunct to Compound Lidocaine Cream - The use of brimonidine tartrate ophthalmic solution as an adjuvant to enhance the analgesic effect of compound lidocaine cream in patients undergoing photoelectric therapy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100068
Enrollment
Unknown
Registered
2025-04-02
Start date
2025-04-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adjunctive analgesia

Interventions

Control side:Study Design: This trial employed a split-face (left-right facial self-control) design. Control Side: Normal saline was applied topically, followed by compound lidocaine cream after ab
Test side:Study Design: This trial employed a split-face (left-right facial self-control) design. Control Side: Normal saline was applied topically, followed by compound lidocaine cream after absor

Sponsors

The Second Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: (1) Male or female subjects aged between 18 and 65 years (inclusive); (2) Diagnosed with one or more of the following skin conditions: skin laxity, enlarged pores, freckles, melasma, or acne scars; (3) Presence of bilaterally symmetrical facial treatment areas; (4) Signed informed consent form obtained prior to enrollment.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: (1) Pregnant or lactating women; (2) Individuals with diagnosed psychiatric disorders; (3) Subjects having scars, dermatological conditions (e.g., active inflammation or open wounds) in the treatment area that may interfere with treatment efficacy assessment, or a history of cutaneous neoplasms; (4) Patients with photosensitivity disorders or recent sun exposure within the past month; (5) History of rosacea or persistent facial erythema; (6) Participation in other clinical trials within the past 30 days; (7) Subjects deemed unsuitable for this study by the investigator.

Design outcomes

Primary

MeasureTime frame
visual analogue scale;

Secondary

MeasureTime frame
Houpt analogue scale;Kuttner analogue scale;

Countries

China

Contacts

Public ContactYangyan Yi

The Second Affiliated Hospital of Nanchang University

yyy02180422@163.com+86 135 0791 3766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026